Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 14 April, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Alembic Pharmaceuticals Ltd

About the Company - Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 16/06/2010 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ2010PLC061123 and registration number is 061123. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 5035.41 Cr. and Equity Capital is Rs. 39.31 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsAlembic Road, Vadodra Gujarat 390003apl.investors@alembic.co.in
http://www.alembicpharmaceuticals.com
Management
NamePosition Held
Mr. Chirayu AminChairman & CEO
Mr. Pranav AminManaging Director
Mr. Shaunak AminManaging Director
Mr. R K BahetiDirector - Finance & CFO
Mr. K G RamanathanIndependent Director
Mr. Pranav ParikhIndependent Director
Mr. Paresh SaraiyaIndependent Director
Dr. Archana HingoraniIndependent Director
Mr. Ashok BaratIndependent Director
Mr. Jai DiwanjiIndependent Director

Alembic Pharmaceuticals Ltd. Share Price Update

Share PriceValue
Today₹987.70
Previous Day₹992.75

Basic Stock Data of Alembic Pharmaceuticals Ltd

Last Updated: April 6, 2024, 5:47 am

Market Cap 19,751 Cr.
Current Price 1,005
High / Low1,094/500
Stock P/E33.4
Book Value 227
Dividend Yield0.77 %
ROCE7.40 %
ROE7.20 %
Face Value 2.00

Data Source: screener.in

Competitors of Alembic Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Beta Drugs Ltd 1,300 Cr. 1,3521,595/66037.4 1480.00 %33.9 %28.6 % 10.0
Amerise Biosciences Ltd 4.16 Cr. 0.630.93/0.54 0.820.00 %2.12 %2.15 % 1.00
Unichem Laboratories Ltd 3,820 Cr. 543580/365 3420.00 %4.58 %7.05 % 2.00
Glaxosmithkline Pharmaceuticals Ltd 33,305 Cr. 1,9662,650/1,22752.0 90.91.62 %36.4 %26.8 % 10.0
Kilitch Drugs (India) Ltd 573 Cr. 356470/15746.0 1040.00 %9.88 %5.40 % 10.0
Industry Average7,800.43 Cr843.5327.08137.140.32%17.38%14.00%6.60

Alembic Pharmaceuticals Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales1,3141,2801,3261,2921,2721,4161,2621,4751,5091,4061,4861,5951,631
Expenses9499601,0901,0541,0301,2681,2551,2441,2741,2031,2871,3871,364
Operating Profit3653202362392421487231235204199208266
OPM %28%25%18%18%19%10%1%16%16%14%13%13%16%
Other Income3252211910100112103
Interest2325479121514141615
Depreciation475153555612367686774666869
Profit before tax31829218320020129-67151154116130135185
Tax %19%19%19%20%14%24%2%12%21%-31%7%-1%2%
Net Profit28624215816417222-66133122153121137180
EPS in Rs14.8812.758.378.348.741.12-3.356.786.207.766.146.959.18

Alembic Pharmaceuticals Ltd Quarterly Chart

Alembic Pharmaceuticals Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales1,4651,5201,8632,0563,1663,1053,1313,9354,6065,3935,3065,6535,997
Expenses1,2461,2681,5061,6532,1592,4902,4883,0613,3833,9134,4324,9705,151
Operating Profit2192523584031,0076156438741,2231,480874682845
OPM %15%17%19%20%32%20%21%22%27%27%16%12%14%
Other Income134447279-398756-223
Interest3815104553182716185059
Depreciation343540447283105115157183287275274
Profit before tax1612063113599365295417491,0001,368625355535
Tax %19%20%24%21%23%23%22%21%20%19%17%4%
Net Profit1301652362837204034135838011,146521342532
EPS in Rs6.908.7712.4915.0138.2021.3921.8931.0043.9758.3326.5017.4027.05
Dividend Payout %20%29%24%23%9%19%18%18%23%24%38%46%

Alembic Pharmaceuticals Ltd Profit & Loss Yearly Chart

Alembic Pharmaceuticals Ltd Growth

Compounded Sales Growth
10 Years:14%
5 Years:13%
3 Years:7%
TTM:8%
Compounded Profit Growth
10 Years:8%
5 Years:-3%
3 Years:-25%
TTM:179%
Stock Price CAGR
10 Years:14%
5 Years:13%
3 Years:-1%
1 Year:94%
Return on Equity
10 Years:21%
5 Years:18%
3 Years:14%
Last Year:7%

Alembic Pharmaceuticals Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital38383838383838383839393939
Reserves3574656388471,5601,8652,1822,6813,1825,0285,1984,3314,431
Borrowings353187109264114897081,1281,747584717722869
Other Liabilities3043584324937186981,0139311,0221,0581,1671,0901,116
Total Liabilities1,0521,0481,2171,6412,4292,6893,9414,7785,9896,7097,1226,1836,455
Fixed Assets2683443975477087999931,1581,5521,7881,7982,3982,603
CWIP58322183933961,0101,5511,8462,1832,304601478
Investments333287504249182361189698
Other Assets7236687961,0091,5411,4441,8962,0192,5732,5022,9023,0873,277
Total Assets1,0521,0481,2171,6412,4292,6893,9414,7785,9896,7097,1226,1836,455

Alembic Pharmaceuticals Ltd Reserves and Borrowings Chart

Alembic Pharmaceuticals Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 1422652401729483293128124491,463552724
Cash from Investing Activity -56-67-81-256-307-486-884-756-731-840-372-448
Cash from Financing Activity -45-229-15187-224-12950359155-597-217-262
Net Cash Flow41-3183417-286-69115-12726-3714

Alembic Pharmaceuticals Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days505654644040614569245668
Inventory Days133143159196266269302356417431406315
Days Payable108129148166264213313237220194178145
Cash Conversion Cycle75706594429651164266261283237
Working Capital Days615950714972936411894118119
ROCE %30%31%44%38%66%29%22%23%24%26%11%7%

Alembic Pharmaceuticals Ltd Financial Efficiency Indicators Chart

Alembic Pharmaceuticals Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters69.48%69.48%69.48%69.48%69.61%69.61%69.61%69.61%69.61%69.61%69.61%69.61%
FIIs6.56%6.41%5.52%5.89%6.02%5.94%5.32%4.99%4.55%4.34%4.51%4.52%
DIIs10.97%11.25%11.42%11.61%11.74%12.15%12.55%12.76%13.32%13.65%14.22%14.51%
Public12.99%12.86%13.58%13.03%12.63%12.30%12.52%12.64%12.53%12.39%11.67%11.36%
No. of Shareholders99,8091,01,6861,23,0591,10,0381,06,4371,01,4571,03,8111,01,86499,52297,60789,55285,212

Alembic Pharmaceuticals Ltd Shareholding Pattern Chart

No. of Alembic Pharmaceuticals Ltd Shareholders

Alembic Pharmaceuticals Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
DSP Mid Cap Fund47660712.23355.45
Kotak Small Cap Fund - Regular Plan38740162.16288.92
DSP ELSS Tax Saver Fund17271231.02128.81
DSP Healthcare Fund13460665.22100.39
DSP Small Cap Fund7661180.4457.14
DSP Top 100 Equity Fund7017551.6652.34
Aditya Birla Sun Life Small Cap Fund5156650.7738.46
Axis Small Cap Fund2356520.117.57
Mahindra Manulife Flexi Cap Fund1700001.1712.68
Aditya Birla Sun Life Pharma & Healthcare Fund1611382.1312.02

Alembic Pharmaceuticals Ltd ROCE Trend

Alembic Pharmaceuticals Ltd EPS Trend

Alembic Pharmaceuticals Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue2.002.002.002.002.00
Basic EPS (Rs.)17.4026.5060.8143.9731.00
Diluted EPS (Rs.)17.4026.5060.8143.9731.00
Cash EPS (Rs.)32.9940.8366.0550.8237.55
Book Value[Excl.RevalReserv]/Share (Rs.)222.36266.47257.80169.25144.19
Book Value[Incl.RevalReserv]/Share (Rs.)222.36266.47257.80169.25144.19
Revenue From Operations / Share (Rs.)287.59269.95274.39244.34208.74
PBDIT / Share (Rs.)36.1847.0479.7565.1446.84
PBIT / Share (Rs.)22.1732.4570.4256.8040.73
PBT / Share (Rs.)19.6131.5569.6053.0439.75
Net Profit / Share (Rs.)18.9726.2356.7242.4731.44
NP After MI And SOA / Share (Rs.)17.4026.5059.9443.9731.00
PBDIT Margin (%)12.5817.4229.0626.6622.44
PBIT Margin (%)7.7012.0225.6623.2419.51
PBT Margin (%)6.8211.6825.3621.7019.04
Net Profit Margin (%)6.599.7120.6717.3815.06
NP After MI And SOA Margin (%)6.059.8121.8417.9914.85
Return on Networth / Equity (%)7.829.9422.9725.7421.49
Return on Capital Employeed (%)9.5811.7925.4925.2623.34
Return On Assets (%)5.537.3117.5613.8312.23
Long Term Debt / Equity (X)0.000.000.030.270.18
Total Debt / Equity (X)0.140.120.030.540.34
Asset Turnover Ratio (%)0.770.730.790.770.86
Current Ratio (X)1.781.672.011.411.31
Quick Ratio (X)0.870.720.850.720.66
Inventory Turnover Ratio (X)0.860.780.930.951.05
Dividend Payout Ratio (NP) (%)57.4752.820.0039.3215.55
Dividend Payout Ratio (CP) (%)31.8334.060.0033.0512.99
Earning Retention Ratio (%)42.5347.180.0060.6884.45
Cash Earning Retention Ratio (%)68.1765.940.0066.9587.01
Interest Coverage Ratio (X)14.1752.1597.8545.2147.96
Interest Coverage Ratio (Post Tax) (X)8.4330.0870.5932.0933.19
Enterprise Value (Cr.)10301.5015131.7919003.4511697.0810722.89
EV / Net Operating Revenue (X)1.822.853.522.542.73
EV / EBITDA (X)14.4916.3712.129.5312.14
MarketCap / Net Operating Revenue (X)1.722.753.522.182.54
Retention Ratios (%)42.5247.170.0060.6784.44
Price / BV (X)2.232.783.703.123.68
Price / Net Operating Revenue (X)1.722.753.522.182.54
EarningsYield0.030.030.060.080.05

Alembic Pharmaceuticals Ltd Profitability Ratios (%)

Alembic Pharmaceuticals Ltd Liquidity Ratios

Alembic Pharmaceuticals Ltd Liquidity Ratios (%)

Alembic Pharmaceuticals Ltd Interest Coverage Ratios (%)

Alembic Pharmaceuticals Ltd Valuation Ratios

Strength and Weakness of Alembic Pharmaceuticals Ltd Stock

StrengthWeakness
  1. The stock has a high average ROCE of 29.25%, which is a positive sign.
  2. The company has higher reserves (2,520.38 cr) compared to borrowings (583.92 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (3.15 cr) and profit (408.38 cr) over the years.
  1. The stock has a high average Working Capital Days of 80.67, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 142.00, which may not be favorable.

FAQ

What is the latest fair value of Alembic Pharmaceuticals Ltd?

The latest fair value of Alembic Pharmaceuticals Ltd is 525.75.

What is the Market Cap of Alembic Pharmaceuticals Ltd?

The Market Cap of Alembic Pharmaceuticals Ltd is 19,751 Cr..

What is the current Stock Price of Alembic Pharmaceuticals Ltd as on 13 April 2024?

The current stock price of Alembic Pharmaceuticals Ltd as on 13 April 2024 is 1,005.

What is the High / Low of Alembic Pharmaceuticals Ltd stocks in FY 2024?

In FY 2024, the High / Low of Alembic Pharmaceuticals Ltd stocks is ₹1,094/500.

What is the Stock P/E of Alembic Pharmaceuticals Ltd?

The Stock P/E of Alembic Pharmaceuticals Ltd is 33.4.

What is the Book Value of Alembic Pharmaceuticals Ltd?

The Book Value of Alembic Pharmaceuticals Ltd is 227.

What is the Dividend Yield of Alembic Pharmaceuticals Ltd?

The Dividend Yield of Alembic Pharmaceuticals Ltd is 0.77 %.

What is the ROCE of Alembic Pharmaceuticals Ltd?

The ROCE of Alembic Pharmaceuticals Ltd is 7.40 %.

What is the ROE of Alembic Pharmaceuticals Ltd?

The ROE of Alembic Pharmaceuticals Ltd is 7.20 %.

What is the Face Value of Alembic Pharmaceuticals Ltd?

The Face Value of Alembic Pharmaceuticals Ltd is 2.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Alembic Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE